EmilyGGreengardMD

Clinical Trials

• Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18

  Active, not recruiting

  Phase 3

• Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27

  Recruiting

• Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06

  Recruiting

• Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2011 Sep 01

  Completed

  Phase 1

• Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12

  Completed

  Phase 2

• Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2013 Jan 31

  Completed

  Phase 1, Phase 2

• MIBG for Refractory Neuroblastoma and Pheochromocytoma Start of enrollment: 2013 Dec 01

  Suspended

  Not Applicable

• Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Start of enrollment: 2013 Sep 03

  Completed

  Phase 1

• Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2014 Mar 28

  Completed

  Phase 1, Phase 2

• Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Start of enrollment: 2014 May 16

  Completed

  Phase 1, Phase 2

• VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01

  Completed

  Phase 1

• A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11

  Completed

  Phase 1

• Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Start of enrollment: 2018 Jan 31

  Active, not recruiting

  Phase 1, Phase 2

• Join now to see all